Integrated Biosciences

Integrated Biosciences

Private
Redwood City, CaliforniaHealthcare & Life Scienceshttps://www.integratedbiosciences.com

Last Round

Seed

Oct 3, 2024

Total Funding Raised

$17.2M

Momentum Score

50 /100

Company Overview

Integrated Biosciences, Inc. is a biotechnology company that develops next-generation therapeutics for age-related diseases. The company combines synthetic biology, artificial intelligence (AI), optogenetics, and chemistry to discover and develop novel small-molecule drug candidates. Its platform allows for precise control over biological systems to identify new drug targets and modulate pathways associated with aging and diseases such as neurodegeneration, cancer, and diabetes. Founded in 2022, the company has raised significant seed funding and is building a portfolio of preclinical assets.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, ML Platforms

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

drug discovery platformAI drug discoveryage-related diseasessmall molecule drugslongevity biotechsynthetic biologycellular stress responsescomputational biologygenerative biologyin silico drug discoverypharmaceutical partnershipsdrug discovery servicespreclinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Integrated Biosciences Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Integrated Biosciences Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
SeedOct 3, 2024

Integrated Biosciences Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 19, 2026

    Tony Wu, Co-Founder of xAI, joins the board.

  • Jan 27, 2026

    Daniel J. Anderson appointed as the new Chief Scientific Officer.

Integrated Biosciences Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Integrated Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Integrated Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersRedwood City, California
Employee Range18
Year Founded2022
Last FundingOct 3, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.